Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28105422 | 0.87 | CDK1 (0.66) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL460228 | 0.87 | CDK1 (0.66) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL27877094 | 0.84 | CDK1 (0.75) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL9393818 | 0.83 | CDK1 (0.65) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL4623411 | 0.83 | CDK1 (0.67) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL29287549 | 0.82 | CDK1 (0.66) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL3507329 | 0.82 | CDK1 (0.66) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL108212 | 0.82 | CDK1 (0.72) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL27801162 | 0.82 | CDK1 (0.72) | CDK1CCNB1CA2CA9LDHA | |
| SCHEMBL27548559 | 0.82 | CDK1 (0.72) | CDK1CCNB1CA2CA9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575122-B2 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8496957-B2 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC (US) | 2013-07-30 | — | — | US | disclosed |
| US-20100273864-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090325938-A1 | CONTROLLED-RELEASE CNS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, S100B | CDK1 2641/4885CCNB1 2963/4885CA2 131/4885 |
| US-20090325938-A1 | CONTROLLED-RELEASE CNS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, SLC18A2, PMP22 | CDK1 2685/4885CCNB1 2790/4885CA2 247/4885 |
| US-20100273864-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, S100B | CDK1 2641/4885CCNB1 2963/4885CA2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.